p.100 抽出テキスト

Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 September 25, 2018 e371 CLINICAL STATEMENTS AND GUIDELINES

S7.4-43.	 Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J. 2011;32:1161–70. S7.4-44.	 Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358:1899–908. S7.4-45.	 Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–57. S7.4-46.	 Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J. 2010;31:1551–3. S7.4-47.	 Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol. 2011;107:604–8. S7.4-48.	 Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42:e59. S7.4-49.	 Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991;325:1753–60. S7.4-50.	 O’Mahony C, Jichi F, Monserrat L, et al. Inverted U-shaped relation between the risk of sudden cardiac death and maximal left ventricular wall thickness in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9:e003818. S7.4-51.	 Saeed M, Homoud MK, Wang PJ, et al. Role of invasive electrophysiologic testing in risk stratification for sudden cardiac death. J Invasive Cardiol. 2001;13:758–62. S7.4-52.	 Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: one gene ... but many phenotypes. Am J Cardiol. 2014;113:1772–3. S7.4-53.	 Ho CY, Cirino AL, Lakdawala NK, et al. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart. 2016;102:1805–12. S7.4-54.	 Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–7. S7.4-55.	 Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118:1541–9. S7.4-56.	 Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of mid-

ventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;57:2346–55.

7.5 Myocarditis

S7.5-1.	 Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J. 2002;66:133–44. S7.5-2.	 Maleszewski JJ, Orellana VM, Hodge DO, et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015;115:1733–8. S7.5-3.	 Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis– natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336:1860–6. S7.5-4.	 Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15–22. S7.5-5.	 Friman G, Wesslen L, Fohlman J, et al. The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J. 1995:16 suppl O:36–41. S7.5-6.	 Hufnagel G, Pankuweit S, Richter A, et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz. 2000;25:279–85. S7.5-7.	 Winkel E, Parrillo J. Myocarditis. Curr Treat Options. Cardiovasc Med. 2002;4:455–66. S7.5-8.	 Zawadowski GM, Klarich KW, Moder KG, et al. A contemporary case series of lupus myocarditis. Lupus. 2012;21:1378–84. S7.5-9.	 Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowl-

edge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–2648d. S7.5-10.	 Elamm C, Fairweather D, Cooper LT, Pathogenesis and diagnosis of

myocarditis. Heart. 2012;98:835–40. S7.5-11.	 Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379:738–47. S7.5-12.	 McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690–5. S7.5-13.	 Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091–100. S7.5-14.	 Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639–48. S7.5-15.	 Tubman TR, Craig B, Mulholland HC. Ventricular tachycardia associated with Coxsackie B4 virus infection. Acta Paediatr Scand. 1990;79:572–5. S7.5-16.	 Tai YT, Lau CP, Fong PC, et al. Incessant automatic ventricular tachycardia complicating acute coxsackie B myocarditis. Cardiology. 1992;80:339–44. S7.5-17.	 Dhar KL, Adlakha A, Phillip PJ. Recurrent seizures and syncope, ventricular arrhythmias with reversible prolonged Q-Tc interval in typhoid myocarditis. J Indian Med Assoc. 1987;85:336–7. S7.5-18.	 McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69. S7.5-19.	 Cooper LT Jr, Elamm C, Giant cell myocarditis. Diagnosis and treatment. Herz. 2012;37:632–6. S7.5-20.	 Milei J, Grana D, Fernandez AG, et al. Cardiac involvement in acquired immunodeficiency syndrome–a review to push action. The Committee for the Study of Cardiac Involvement in AIDS. Clin Cardiol. 1998;21:465–72. S7.5-21.	 Yunis NA, Stone VE, Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:145–54. S7.5-22.	 Huang CN, Yu HH, Chiu SN, et al. Acute myocarditis and ventricular fibrillation as initial presentation of pediatric systemic lupus erythematosus. Rheumatol Int. 2013;33:1093–6. S7.5-23.	 Rassi A Jr, Rassi A, Little WC, Chagas’ heart disease. Clin Cardiol. 2000;23:883–9. S7.5-24.	 Muratore C, Rabinovich R, Iglesias R, et al. Implantable cardioverter defibrillators in patients with Chagas’ disease: are they different from patients with coronary disease? Pacing Clin Electrophysiol. 1997;20:194–7. S7.5-25.	 d’Avila A, Splinter R, Svenson RH, et al. New perspectives on catheter-based ablation of ventricular tachycardia complicating Chagas’ disease: experimental evidence of the efficacy of near infrared lasers for catheter ablation of Chagas’ VT. J Interv Card Electrophysiol. 2002;7:23–38. S7.5-26.	 Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123. S7.5-27.	 Feldman AM, Klein H, Tchou P, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol. 2004;27:4–9. S7.5-28.	 Cooper LT, Okura Y. Idiopathic giant cell myocarditis. Curr Treat

Options Cardiovasc Med. 2001;3:463–7.

7.6 Cardiac Sarcoidosis

S7.6-1.	 Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131:624–32. S7.6-2.	 Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of longterm survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–10. S7.6-3.	 Kron J, Sauer W, Schuller J, et al. Efficacy and safety of implant-

able cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace. 2013;15: 347–54.

Downloaded from http://ahajournals.org by on October 7, 2026